Lower-Carbon Beclometasone Inhalers Approved by the MHRA for Asthma

Introduction

Lower-carbon beclometasone inhalers have been approved by the MHRA, marking a significant step for asthma care in the UK. The approval covers new versions of two established inhalers and introduces a next-generation propellant designed to reduce environmental impact, while the underlying treatment remains unchanged for patients.

MHRA Approves New Versions of Clenil Modulite

On 21 July 2026, the Medicines and Healthcare products Regulatory Agency approved new versions of Clenil Modulite 100 micrograms inhaler and Clenil Modulite 200 micrograms inhaler. Both contain beclometasone dipropionate for the maintenance treatment of asthma in adults and children.

This approval is the world’s first authorisation of pressurised metered-dose inhalers using the next-generation propellant HFA-152a. The propellant is not an active medicine but is used to deliver the inhaled dose.

The new versions will be available in the UK later in 2026. Until then, the current versions of Clenil Modulite will continue to be available to patients.

Why Lower-Carbon Beclometasone Inhalers Matter

Asthma is a common long-term condition affecting the airways in the lungs. Symptoms can include wheezing, coughing, chest tightness, and shortness of breath. Inhalers play a vital role in helping patients manage the condition and maintain their quality of life.

According to the MHRA, the approval shows how innovation can support both patient care and environmental sustainability, while maintaining the high standards of quality, safety and effectiveness that patients expect.

What Stays the Same for Patients

No changes have been made to the active ingredient, recommended doses or therapeutic indications. The active ingredient, beclometasone dipropionate, is a corticosteroid that reduces inflammation in the airways, helping to prevent asthma symptoms and exacerbations.

The MHRA’s approval is supported by evidence demonstrating that the new formulations perform comparably to the currently authorised products, maintaining the same quality, safety, and clinical benefit. The medicine is administered via a pressurised metered-dose inhaler and used regularly to help prevent asthma symptoms.

Side Effects and Safety Monitoring

The most common side effects of beclometasone inhalers include oral thrush, hoarseness of the voice, and throat irritation. A full list of side effects for the current version can be found in the Patient Information Leaflet or the Summary of Product Characteristics, which will be updated when the new version becomes available.

As with any medicine, the MHRA will keep the safety and effectiveness of beclometasone dipropionate under close review. Anyone who suspects they are experiencing a side effect should speak to their doctor, pharmacist or nurse and report it through the Yellow Card scheme.

Conclusion

The approval of lower-carbon beclometasone inhalers combines established asthma treatment with a next-generation propellant designed to reduce environmental impact. With no changes to the active ingredient, dose or indications, patients can expect the same clinical benefit as the new formulations become available in the UK later in 2026.